32. Pathologe. 2018 Jul 17. doi: 10.1007/s00292-018-0456-4. [Epub ahead of print][Revised version of the 4th edition of the WHO classification of malignantlymphomas : What is new?][Article in German]Ott G(1), Klapper W(2), Feller AC(3), Hansmann ML(4), Möller P(5), Stein H(6),Rosenwald A(7), Fend F(8).Author information: (1)Abteilung für Klinische Pathologie, Robert-Bosch-Krankenhaus, und Dr.Margarete Fischer-Bosch-Institut für Klinische Pharmakologie,Auerbachstraße 110/112, 70376, Stuttgart, Deutschland. german.ott@rbk.de.(2)Institut für Pathologie, Sektion Hämatopathologie, UniversitätsklinikumSchleswig-Holstein, Campus Kiel, Kiel, Deutschland.(3)Hämatopathologie Lübeck, Lübeck, Deutschland.(4)Senckenberg Institut für Pathologie, Universitätsklinikum Frankfurt,Frankfurt, Deutschland.(5)Institut für Pathologie, Universitätsklinikum Ulm, Ulm, Deutschland.(6)Pathodiagnostik Berlin, Berlin, Deutschland.(7)Pathologisches Institut und Comprehensive Cancer Center Mainfranken,Universität Würzburg, Würzburg, Deutschland.(8)Institut für Pathologie und Neuropathologie, Eberhard-Karls-Universität,Tübingen, Deutschland.After 8 years, the WHO has now published the updated version of the 4th editionof the classification of hematopoietic and lymphoid tumors. This update provides a conceptual rewrite of existing entities as well as some new provisionalentities and categories, particularly among the aggressive B‑cell lymphomas.Important new diagnostic categories include the high-grade B‑cell lymphomas, the large B‑cell lymphoma with IRF4 rearrangement, and the Burkitt-like lymphoma with11q aberrations. Of particular importance, new concepts concerning the taxonomyand classification of early lymphoid lesions or precursor lesions are included,such as the in situ follicular neoplasia or the in situ mantle cell neoplasia. Inaddition, the concept of indolent lymphoproliferations, such asbreast-implant-associated anaplastic large cell lymphoma and the indolent T‑cell lymphoproliferative disorder of the gastrointestinal tract, has beenstrengthened. Finally, diagnostic criteria for existing lymphoma entities havebeen refined.DOI: 10.1007/s00292-018-0456-4 PMID: 30019203 